MedTrace Logo

Magnesium Supplementation in Simultaneous Pancreas-Kidney Transplantation

NCT06766786 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-01-09

No results posted yet for this study

Summary

Magnesium is essential in human physiology. Simultaneous pancreas-kidney (SPK) transplant recipients frequently experience hypomagnesemia. The effects of hypomagnesaemia are harmful. This observational study assessed intraoperative magnesium supplementation's utility in patients undergoing SPK transplantation. Perioperative hemodynamics were monitored. Postoperative serum magnesium was monitored at 12 hours and 48 hours.

Conditions

  • Renal Failure Chronic Requiring Dialysis
  • Diabetes Mellitus, with Complications
  • Glomerulosclerosis
  • Pancreatic Insufficiency (Exocrine and Endocrine)
  • Transplantation, Kidney
  • Pancreas Transplantation

Interventions

DRUG

Magnesium Sulfate high dose

Patients undergoing simultaneous pancreas-kidney (SPK) transplantation who gave their consent were given an intravenous magnesium supplement at a dose of 45-50 mg/kg over the course of an hour during the procedure.

Sponsors & Collaborators

  • Central Manchester University Hospitals NHS Foundation Trust (co-sponsor, UK)

    collaborator UNKNOWN

  • Dr Olu Bamgbade, MD, FRCPC

    lead OTHER

Principal Investigators

  • Olumuyiwa Bamgbade, MD, FRCPC · Salem Anaesthesia Pain Clinic

Eligibility

Min Age
20 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-02
Primary Completion
2020-02-20
Completion
2020-02-20

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06766786 on ClinicalTrials.gov